Mary E. Guckert
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Oncology top 1%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Multiple Myeloma Research and Treatments 6
-
- Synthesis and Biological Evaluation 3
- Synthesis and biological activity 1
- Co-authors
- Antoni Ribas (1 shared paper)Ester Simeone (1 shared paper)Anne O’Hagan (1 shared paper)David R. Minor (1 shared paper)Vicki L. Goodman (1 shared paper)Anne-Marie Martin (1 shared paper)Uwe Trefzer (1 shared paper)Kevin B. Kim (1 shared paper)
- Journals
- Blood (5 papers)Journal of Clinical Oncology (2 papers)The Lancet Oncology (2 papers)The Lancet (1 paper)New England Journal of Medicine (1 paper)
- Partner nations
- United StatesUnited KingdomDenmark
In The Last Decade
Mary E. Guckert
12 papers receiving 5.1k citations
Mary E. Guckert's Hit Papers
Peers
Comparison fields: 5 of 90
- Hematology 1.3k
- Oncology 2.6k
- Molecular Biology 3.2k
- Genetics 423
- Cancer Research 320
Countries citing papers authored by Mary E. Guckert
This map shows the geographic impact of Mary E. Guckert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Guckert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Guckert more than expected).
Fields of papers citing papers by Mary E. Guckert
This network shows the impact of papers produced by Mary E. Guckert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Guckert. The network helps show where Mary E. Guckert may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary E. Guckert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2012 | 2523 |
| 2 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1200 |
| 3 | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Hit paper breakdown → | 2012 | 768 |
| 4 | 2013 | 372 | |
| 5 | 2016 | 101 | |
| 6 | 2009 | 69 | |
| 7 | 2009 | 56 | |
| 8 | 2014 | 46 | |
| 9 | 2015 | 35 | |
| 10 | 2016 | 25 | |
| 11 | 2016 | 15 | |
| 12 | Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365 | 2012 | 6 |
About Mary E. Guckert
Mary E. Guckert is a scholar working on Hematology, Organic Chemistry, Molecular Biology, Genetics and Surgery, having authored 12 papers that have together received 5.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (6 papers), Synthesis and Biological Evaluation (3 papers), Melanoma and MAPK Pathways (3 papers), Protein Degradation and Inhibitors (2 papers), Nausea and vomiting management (2 papers), Cancer therapeutics and mechanisms (2 papers), Synthesis and biological activity (1 paper) and Chronic Lymphocytic Leukemia Research (1 paper). The work is most often cited by research in Hematology (1.3k citations), Oncology (2.6k citations), Molecular Biology (3.2k citations), Genetics (423 citations) and Cancer Research (320 citations). Mary E. Guckert has collaborated with scholars based in United States, United Kingdom and Denmark. Frequent co-authors include Antoni Ribas, Ester Simeone, Anne O’Hagan, David R. Minor, Vicki L. Goodman, Anne-Marie Martin, Uwe Trefzer, Kevin B. Kim, Ravi K. Amaravadi and Niki Arya. Their work appears in journals such as Blood, Journal of Clinical Oncology, The Lancet Oncology, The Lancet and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.